<DOC>
	<DOCNO>NCT01168687</DOCNO>
	<brief_summary>The overall goal study ( 1 ) expand knowledge interaction levetiracetam alcohol assess effect levetiracetam compare placebo moderate heavy social alcohol user ( 2 ) test AccuswayTM platform tool measure postural control ( use marker intoxication ) effect levetiracetam postural control .</brief_summary>
	<brief_title>Effects Levetiracetam ( Keppra ) Alcohol Consumption</brief_title>
	<detailed_description>The investigator propose 42-day , double-blind , placebo-controlled crossover study light moderate heavy alcohol user social drinker . The specific aim : 1 . Determine levetiracetam alters daily alcohol consumption compare mean drink consume per day levetiracetam administration compare mean drink per day consume placebo administration . 2 . Obtain blood banked future genetic analysis polymorphism gene may predict level response alcohol effect levetiracetam alcohol consumption . 3 . Test whether AccuswayTM platform detect change body sway light moderate heavy social drinker subject take levetiracetam versus placebo .</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>1 . Healthy adult social drinker 21 50 year age . 2 . Moderate heavy social drinker ( women=721 drinks/week , men=725 drinks/week ) . 3 . Body Mass Index ( BMI ) &gt; 18 &lt; 30 . 4 . If female , must nonlactating , pregnant , use reliable contraception method ( i.e . abstinence , intrauterine device [ IUD ] , hormonal birth control , double barrier method [ male condom , female condom , diaphragm plus spermicidal agent contraceptive foam , jelly cream ] ) . 5 . Able willing provide write informed consent . 6 . Able understand follow instruction investigator , understand rating scale . 7 . Have negative urine drug screen visit , exception cannabinoids . 1 . Positive urine drug screen , except cannabinoids . Occasional cannabinoid use allow , however daily use , dependence , consider casual user study physician , subject exclude . 2 . Use cocaine , amphetamines stimulant , hallucinogen , ecstasy psychoactive drug , great 10 time last 24 month anytime past 60 day . 3 . Lifetime use PCP ketamine great 10 time , time last 24 month . 4 . History abuse inhalant ( glue , toluene volatile substance ) . 5 . Current past dependence , addiction psychoactive drug ( except nicotine caffeine ) include alcohol , determine study physician 's assessment . 6 . Current prior enrollment alcohol drug treatment program , current legal problem relate alcohol drug use , include await trial supervision parole probation officer . 7 . Binge drinking three time per week ( binge define &gt; 5 standard drink one session ) . 8 . Alcohol consumption &gt; 21 drinks/week woman &gt; 25 drinks/week men . 9 . Currently try quit alcohol and/or recreational drug use . 10 . Positive lifetime abnormal opioid use prescription drug abuse . 11 . Clinically significant medical psychiatric illness ( include anxiety panic disorder ) determine screen blood test , medical history , physical exam perform review study physician . 12 . Bilirubin 2 time normal upper limit . 13 . AST ( SGOT ) , ALT ( SGPT ) , alkaline phosphatase 2 time normal upper limit . 14 . Body Mass Index &gt; 30 &lt; 18 15 . Pregnancy woman child bear potential currently use adequate mean contraception . 16 . Currently take medication overthecounter nonsteroidal antiinflammatories , acetaminophen , inhale asthma therapy , contraceptive , nicotine patch , overthecounter nonsedating antihistamines.NSAIDs , acetaminophen , OTC ( include herbal ) medication ( unless clear study physician ) . 17 . BAC level great 0.02 % begin visit 1 , 7 , 8 ( within margin error detection ) . 18 . Estimated creatinine clearance &lt; 50 ml/min . 19 . Chronic pain condition require regular physician visit treatment physician 's supervision . 20 . Neurological dysfunction psychiatric disorder severe enough interfere assessment outcome measure define . 21 . Allergy levetiracetam . 22 . Significant cardiac pathology abnormal initial EKG QT/QTc interval prolongation &gt; 480 secs baseline . 23 . Has receive investigational drug within 30 day prior Study Visit 2 ( screen visit ) . 24 . Subjects unable read speak English . 25 . Those , opinion investigator , consider unable adhere schedule appointment , unlikely comply study protocol , unsuitable reason .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>keppra</keyword>
	<keyword>levetiracetam</keyword>
	<keyword>alcoholism</keyword>
	<keyword>genetics</keyword>
	<keyword>subjective report</keyword>
</DOC>